Comprehensive Analysis of the Expression and Clinical Significance of RAS Family Members in Non-Small Cell Lung Cancer Based on Bioinformatics Data and the A549 Cell Line Model

Lung cancer is the second most frequent worldwide diagnosed cancer. Mutations in RAS genes family are among common oncogenic alterations occurring non-small cell lung (NSCLC). Many treatment options against KRAS mutations have been developed for NSCLC; however, they remain insufficient. Moreover, role of and HRAS gene expression remains unclear. However, inhibitors seem to be a good candidate new drugs agents NSCLC. This study used bioinformatical analysis determine its clinical significance, then examined influence three different (farnesythiosalicylic acid (FTS), deltarasin Kobe0065) on growth (by RT-qPCR) human NSCLC A549 cells. were shown overexpressed compared non-tumor tissues healthy individuals (from databases) significantly associated with clinicopathological features. It was also found that FTS, dose-dependent manner, suppressed proliferation cells, while reduced To sum up, results obtained from analyses based bioinformatics databases indicate studied potential risk factors development On other hand, studies their lines indicated may potentially important response using inhibitors.